The Efficiency of Sunitinib in Chinese Patients with Advanced Well-differentiated Pancreatic Neuroendocrine Tumor

#1385

Introduction: Systemic therapies for advanced Pancreatic neuroendocrine tumors (pNETs) are various. Sunitinib has shown its efficiency in pNET in clinical trials. While the efficiency of sunitinib in Chinese pNETs has not reported yet.

Aim(s): To describe clinical outcomes of Chinese advanced pNETs patients(pts) treating with sunitinb, and compare the efficiency of sunitinb in first-line therapy and post-second line therapy in pNETs.

Materials and methods: Advanced pNET pts who accepted sunitinib treatment after disease progression were collected from April 2009 to May 2015. pts received sunitinib 37.5 mg/day or 25mg/d if intolerable, on a continuous daily dosing schedule. Data examined included clinicopathological characteristics and outcomes.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gao H

Authors: Gao H, Cheng Y, Bai C,

Keywords: sunitinib, Chinese, pNET, efficiency,